Risks of troglitazone apparent before approval in USA [4]

Diabetologia

Volumn 49, Issue 6, 2006, Pages 1454-1455

  Cohen, J S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ERYTHROMYCIN; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; TROGLITAZONE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG MARKETING; EVIDENCE BASED MEDICINE; HUMAN; JAUNDICE; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

CHROMANS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 33646511583     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0245-0     Document Type: Letter

References (6)

1. Gale EAM (2006) Troglitazone: the lesson that nobody learned? Diabetologia 49:1-6
2. Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917
3. Physicians' desk reference, 52nd and 54th edn. (1998 and 2000) Medical Economics Company, Montvale, New Jersey
4. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271:992-998
5. Graham DJ, Drinkard CR, Shatin D (2003) Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 98:175-179
6. Kaplowitz N (2003) Drug-induced liver disorders: introduction and overview. In: Kaplowitz N, DeLeve LD (eds) Drug-induced liver disease. Marcel Dekker, New York, pp 1-14